Avacta Group PLC represents a strong commitment to innovation, excellence, and high-quality solutions in the healthcare sector. By focusing on developing and commercializing novel biotherapeutics and diagnostics, Avacta Group aims to improve patient outcomes and transform the way diseases are diagnosed and treated. Their corporate philosophy is centered around collaboration, strategic partnerships, and delivering value for all stakeholders. Avacta Group PLC constantly strives to stay at the forefront of cutting-edge technologies and leverage their expertise to address significant medical challenges. With a relentless drive for scientific advancements, Avacta Group PLC aims to revolutionize healthcare by providing innovative and effective solutions to improve global health.

Avacta Group PLC is primarily present in the United Kingdom (UK).

Avacta Group PLC, a leading biotechnology company, has achieved several significant milestones. Firstly, they successfully developed a novel Affimer® technology, revolutionizing the field of protein engineering. Avacta also secured multiple key partnerships with industry leaders, such as LG Chem Life Sciences and Tufts University, to accelerate commercialization. Furthermore, the company obtained regulatory approval for their rapid COVID-19 antigen test, demonstrating their commitment to public health. Avacta received the CE Mark certification for its clinically validated SARS-CoV-2 rapid antigen test, facilitating global distribution. Such accomplishments highlight Avacta Group PLC's dedication to innovation, collaborations, and advancing healthcare solutions.

Avacta Group PLC is a leading biotechnology company, specializing in the development and commercialization of cutting-edge technologies. With a rich history and strong background, Avacta has been at the forefront of innovative solutions since its inception. Established in 2004 and headquartered in the United Kingdom, Avacta has built a solid reputation for its expertise in Affimer® technology, an alternative to antibodies. Avacta's extensive portfolio includes products and services for various sectors, including diagnostics, therapeutics, and research. With a commitment to revolutionizing the healthcare industry, Avacta Group PLC continues to drive advancements in precision medicine and deliver transformative solutions for global health challenges.

The main competitors of Avacta Group PLC in the market are companies like Abcam, Bio-Rad Laboratories, and Thermo Fisher Scientific.

Avacta Group PLC is primarily active in the biotechnology and healthcare industries.

The business model of Avacta Group PLC revolves around the development and commercialization of innovative life science tools and technologies. Avacta Group specializes in the development of Affimer® platform, a versatile technology with multiple applications in diagnostics, therapeutics, and research. The company aims to leverage its proprietary technology to provide solutions for various sectors including biotechnology, healthcare, and pharmaceuticals. Avacta Group focuses on collaborations and partnerships to accelerate commercialization and maximize the potential of its Affimer® platform. Through its dedication to innovation and strategic partnerships, Avacta Group aims to drive growth and create value for shareholders and stakeholders.

Коефициентът на цена спрямо печалбата (КЦП) на Avacta Group е -5,30.

Коефициентът на цена към оборот (KUV) на Avacta Group е 7,53.

AlleAktien качественият резултат за Avacta Group е 6/10.

очаквана Avacta Group оборотът е 24,88 млн. GBP.

очаквана Avacta Group печалба е -35,37 млн. GBP.

The Avacta Group PLC is a biotechnology and diagnostics company specialized in the development and commercialization of technologies and applications in the life sciences and healthcare sectors. The company offers innovative products and services for disease detection and treatment, as well as pharmaceutical research. It operates in two business areas: "Life Sciences" and "Animal Health." The "Life Sciences" business focuses on providing tools and services for drug discovery and therapy development, particularly in the field of recombinant affinity reagents. The "Animal Health" business concentrates on developing diagnostic tests for various animals, including dogs, cats, horses, and cattle. Avacta's products include affinity reagents, reactive surfaces, assays, and devices for both research and clinical use. The company has also developed a proprietary immunoclonal format called Affimer, which is an alternative to antibodies for biomarker detection and quantification. Avacta offers custom services for Affimer applications. Established in 2004, Avacta Group is listed on the London Stock Exchange and headquartered in Wetherby, Yorkshire, with additional offices in Cambridge and San Diego. The company collaborates with customers and partners in the biotechnology, pharmaceutical, and diagnostics sectors to develop innovative products. It aims to expand its leadership position in biotechnology and diagnostics by continually enhancing its product and service pipeline.Most relevantly, Avacta Group provides a wide range of products and services in the life sciences and animal health sectors, employing advanced technologies for disease detection and treatment. It is committed to promoting biotechnological research and development and delivering innovative products for clinical application.

Avacta Group разпределя дивидента от 0 GBP на плащания годишно.

Дивидентата за Avacta Group в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Avacta Group е GB00BYYW9G87.

WKN на Avacta Group е A2ADP0.

Тикерът на Avacta Group е AVCT.L.

През последните 12 месеца Avacta Group изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Avacta Group да изплати дивиденда в размер на 0 GBP.

Дивидентната доходност на Avacta Group в момента е .

Avacta Group изплаща дивидент на тримесечие. Той се разпределя в месеците .

Avacta Group платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 GBP. Това съответства на дивидентна доходност от 0 %.

Avacta Group се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Avacta Group на 13.08.2024 г. в размер на 0 GBP, трябваше да притежавате акцията в портфейла си преди Ex-деня на 13.08.2024 г..

Последното дивидентно плащане беше извършено на 13.08.2024 г..

През година 2023 Avacta Group изплати 0 GBP под формата на дивиденти.

Дивидентите от Avacta Group се изплащат в GBP.